DIOVAN 80MG FILM COATED TABLETS Ciprus - görög - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

diovan 80mg film coated tablets

novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - valsartan - film coated tablets - 80mg - valsartan (8000001531) 80mg - valsartan

DIOVAN TABLET 80 mg Szingapúr - angol - HSA (Health Sciences Authority)

diovan tablet 80 mg

novartis (singapore) pte ltd - valsartan - tablet, film coated - 80 mg - valsartan 80 mg

CO-DIOVAN 16012.5 MG FILM-COATED TABLETS Izrael - angol - Ministry of Health

co-diovan 16012.5 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

DIOVAN valsartan 80mg film-coated tablet blister pack Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

diovan valsartan 80mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 8000; iron oxide yellow; iron oxide red - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").

Diovan Tab 80 mg Jordánia - angol - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

diovan tab 80 mg

شركة مستودع الأدوية الأردني - the jordan drugstore co - valsartan 80 mg - 80 mg

DIOVAN Tablets 80mg (ディオバン錠80mg) Japán - angol - すりの適正使用協議会 RAD-AR Council, Japan

diovan tablets 80mg (ディオバン錠80mg)

novartis pharma k.k. - valsartan - white tablet, diameter: 8.6 mm, thickness: 3.7 mm

Co-Diovan 80mg/12.5mg tablets Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

co-diovan 80mg/12.5mg tablets

novartis pharmaceuticals uk ltd - valsartan; hydrochlorothiazide - oral tablet - 80mg ; 12.5mg

CO-DIOVAN 80/12.5 valsartan 80 mg and hydrochlorothiazide 12.5 mg tablet blister pack Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

co-diovan 80/12.5 valsartan 80 mg and hydrochlorothiazide 12.5 mg tablet blister pack

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; crospovidone; purified talc; magnesium stearate; hypromellose; macrogol 8000; iron oxide red; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

DIOVAN OD Tablets 80mg (ディオバンOD錠80mg) Japán - angol - すりの適正使用協議会 RAD-AR Council, Japan

diovan od tablets 80mg (ディオバンod錠80mg)

novartis pharma k.k. - valsartan - white tablet, diameter: 9.5 mm, thickness: 5.4 mm

DIOVAN 40 MG FILM-COATED TABLETS Izrael - angol - Ministry of Health

diovan 40 mg film-coated tablets

novartis israel ltd - valsartan - film coated tablets - valsartan 40 mg - valsartan - valsartan - diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan significantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.